Bleeding incidence and risk factors among cancer patients treated with anticoagulation
Benjamin Crichi, Le 1er Juillet 2019
Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study
Dr. Corinne FRERE, Le 1er Juin 2019
Rivaroxaban thromboprohylaxis in ambulatory patients with pancreatic cancer: Results from a prespecified subgroup analysis of the CASSINI study
Dr. Corinne FRERE, Le 1er Juin 2019
Arterial thromboembolic events preceding the diagnosis of cancer in older persons.
Dr. Corinne FRERE, Le 05 Mai 2019
Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis.
Dr. Corinne FRERE, Le 05 Mai 2019
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.
Dr. Corinne FRERE, Le 08 Avril 2019
The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis.
Dr. Corinne FRERE, Le 22 février 2019
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.
Dr. Corinne FRERE, Le 21 février 2019
Pharmacokinetic variability of anticoagulants in patients with cancer associated thrombosis: Clinical consequences
Dr. Ilham BENZIDIA, Le 30 janvier 2019
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
Dr. Corinne FRERE, Le 04 décembre 2018
Cancer associated thrombosis in patients with implanted ports: a prospective multicenter French cohort study (ONCOCIP)
Dr. José Antonio RUEDA CAMINO, Le 12 novembre 2018
Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study
Dr Ilham BENZIDIA, Le 06 novembre 2018
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
José Antonio RUEDA CAMINO, Le 23 octobre 2018
Clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts.
Dr. Corinne FRERE, Le 10 septembre 2018
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness
Dr. Corinne FRERE, Le 10 septembre 2018
Bleeding and venous thromboembolic events in patients with active cancer hospitalized for an acute medical illness.
Dr. Corinne FRERE, Le 27 août 2018
Venous Thromboembolic Events Following Major Pelvic and Abdominal Surgeries for Cancer: A Prospective Cohort Study.
Dr. Corinne FRERE, Le 25 août 2018
Risk associated with central catheters for malignant tumor patients: a systematic review and meta-analysis.
Dr. Roxane GAÏSSET, Le 18 Juin 2018
Quality of life in cancer patients undergoing anticoagulant treatment with LMWH for venous thromboembolism: the QUAVITEC study on behalf of the Groupe Francophone Thrombose et Cancer (GFTC)
Dr. Ilham BENZIDIA, Le 07 Juin 2018
Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer.
Dr. Corinne FRERE, Le 07 Juin 2018
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
Dr. Corinne FRERE, Le 16 Mai 2018
Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer
Dr. Corinne FRERE, Le 03 Mai 2018
What Impact Does Venous Thromboembolism and Bleeding Have on Cancer Patients’ Quality of Life?
Dr. Corinne FRERE, Le 02 Mai 2018
Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism-Analysis of the CATCH Study.
Dr. Corinne FRERE, Le 07 Avril 2018
Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study.
Dr. Corinne FRERE, Le 05 Avril 2018
Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis.
Dr. Corinne FRERE, Le 17 Mars 2018
Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation.
Dr. Corinne FRERE, Le 16 Mars 2018
Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: review of the literature on current practice and emerging options.
Cihan Ay, Pieter Willem Kamphuisen, Giancarlo Agnelli, Le 18 Février 2018
Association of androgen deprivation therapy and thromboembolic events: a systematic review and meta-analysis.
Dr. Francis CAJFINGER & Dr. Corinne FRERE, Le 02 Février 2018
Predicting the risk of recurrent venous thromboembolism in patients with cancer: A prospective cohort study.
Dr. Francis CAJFINGER & Dr. Corinne FRERE, Le 01 Février 2018
Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study.
Dr. Corinne FRERE, Le 27 Janvier 2018
Vitamin K Antagonists after 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism.
Dr. Corinne FRERE, Le 09 Janvier 2018
Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism
Dr. Juliette PENICHOUX, Le 20 décembre 2017
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Dr. Corinne FRERE, Le 12 décembre 2017
Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial
Dr. Corinne FRERE, Le 1er décembre 2017
Association of Warfarin Use with Lower Overall Cancer Incidence Among Patients Older Than 50 Years
Dr. Francis CAJFINGER, Le 1er décembre 2017
Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial
Dr. Ilham BENZIDIA, Le 1er décembre 2017
Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK)
Dr. Corinne FRERE, Le 8 novembre 2017
Randomized Phase III Trial of Low Molecular Weight Heparin Enoxaparin in Addition to Standard Treatment in Small Cell Lung Cancer: the RASTEN Trial.
Dr Francis CAJFINGER, Le 7 novembre 2017
Efficacité et sécurité de l’anticoagulation additive chez les patients avec cancer du poumon, sans indication d’anticoagulant
Screening for cancer in patients with unprovoked venous thromboembolism: protocol for a systematic review and individual patient data meta-analysis.
Dr Mathilde Damilleville, Le 6 novembre 2017
Clinical course of isolated distal deep vein thrombosis in patients with active cancer: a multicenter cohort study.
Dr Bénédicte MARCQ, Le 03 Novembre 2017
Incidence, risk factors, and outcomes of central venous catheter-related thromboembolism in breast cancer patients: the CAVECCAS study.
Dr Corinne FRERE, Le 20 Octobre 2017
Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients.
Dr Mathilde Damilleville, Le 20 Octobre 2017
Predictors of active cancer thromboembolic outcomes. RIETE experience of the Khorana score in cancer-associated thrombosis.
Dr Mathieu JAMELOT, Le 15 septembre 2017
Increased risk of arterial thromboembolism in older men with breast cancer.
Dr Francis CAJFINGER, Le 15 septembre 2017
The impact of initial cancer stage on the incidence of venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) Cohort.
Dr Mathieu JAMELOT, Le 5 septembre 2017
Statin use and venous thromboembolism in cancer: A large, active comparator, propensity score matched cohort study
Dr Francis Cajfinger, Le 28 août 2017
Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism: A Systematic Review and Meta-analysis of Individual Patient Data.
Dr Francis Cajfinger, Le 28 août 2017
Risk of Arterial Thromboembolism in Patients With Cancer
Dr Francis Cajfinger, Le 28 août 2017
Incidence and Timing of Thromboembolic Events in Patients With Ovarian Cancer Undergoing Neoadjuvant Chemotherapy.
Dr Francis Cajfinger, Le 10 juin 2017
Extended Duration Enoxaparin Decreases the Rate of Venous Thromboembolic Events After Radical Cystectomy Compared With Inpatient Only Subcutaneous Heparin
Dr Francis Cajfinger, Le 05 Février 2017
Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial
Dr Francis Cajfinger, Le 15 Janvier 2017
Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy
Dr Francis Cajfinger, Le 28 novembre 2016
Chemotherapy, Genetic Susceptibility, and Risk of Venous Thromboembolism in Breast Cancer Patients.
Dr Francis Cajfinger, Le 7 Novembre 2016
Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study.
Dr Corinne Frère, Le 1er novembre 2016
Efficacy of Prophylactic Low–Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial
Uwe Pelzer, Bernhard Opitz, Gerd Deutschinoff, Martina Stauch, Peter C. Reitzig, Sabine Hahnfeld, Lothar Müller, Martina Grunewald, Jens M. Stieler, Marianne Sinn, Timm Denecke, Sven Bischoff,Helmut Oettle, Bernd Dörken, and Hanno Riess, Le 31 Octobre 2015
When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data.
Jerémy Bendavid, Le 7 Octobre 2016
Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation
Therapy.
Dr Francis Cajfinger, Le 1 octobre 2016
Update of thrombosis in multiple myeloma
Dr Francis Cajfinger, Le 24 Juillet 2016
Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism
Dr Francis Cajfinger, Le 23 Juillet 2016
Preoperative Chemoprophylaxis Is Safe in Major Oncology Operations and Effective at Preventing Venous Thromboembolism
Dr Harry Sitbon, Le 10 Mars 2016
Direct signaling between platelets and cancer cells induces an Epithelial Mesenchymal Like Transition and promotes metastasis
Dr Myriam Labelle, Dr Shahinoor Begum and Dr Richard O.Hynes, 23 Février 2016
Survival Effects of Inferior Vena Cava Filter in Patients With Acute Symptomatic Venous Thromboembolism and a Significant Bleeding Risk
Dr Harry Sitbon, Le 06 Janvier 2016
Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial.
Dr Francis Cajfinger, Dr Corinne Frère, Le 03 Janvier 2016
The origin and concentration of circulating microparticles differ according to cancer type and evolution: A prospective single-center study.
Dr Corinne Frère, 09 Octobre 2015
Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY Trial.
Dr Corinne Frère, Le 28 septembre 2015
Screening for Occult Cancer in Unprovoked Venous Thromboembolism.
Dr Corinne Frère, Le 25 septembre 2015
Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Dr Corinne Frère, Le 23 septembre 2015
Cancer predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis
Soraya Mezouar, 10 septembre 2015
Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer : a sytematic
Dr Harry Sitbon, 10/03/2015
Phisicians compliance with the Padua Predition Score for preventing venous thromboembolism among hospitalized medical patients
Dr Jean-Marc Renaudin, 11/02/2015
Prophylaxie primaire de la maladie thromboembolique veineuse chez les patients cancéreux ambulatoires
P. Debourdeau , 07/02/2015
Et si le bevacizumab protegeait des evenements thrombo emboliques veineux ?
F. Cajfinger , 06/12/2014
PICC lines : fin de l’histoire ou utilisation raisonnée ?
P. Debourdeau, 06/09/2013
Les scores pour prédire les risques de saignements majeur sous anticoagulant oral une etude prospective
Laure Avenin, 05/09/2013
L’effet de la coagulation à dose thérapeutique sur la survie globale chez les hommes avec un cancer prostatique metastatique ( résistant à la castration) par docetaxel
F. Cajfinger , Juin 2013
Forte incidence de MTEV en dépit de la surveillance électronique pour thromboprophylaxie chez les patients hospitalisés pour cancer.
P. Debourdeau , Mai 2013
Coût des soins de santé aux US d’une MTEV associé à un cancer à haut risque traité par chimiotherapie
P. Debourdeau , Mai 2013
Nomograme de prédiction du risque de MTEV apres Chirurgie thoracique et abdominal
P. Debourdeau , Avril 2013
Les HBPM en prévention et curatif de la thrombose chez le patient avec cancer
P. Debourdeau , Mars 2013
Efficacité et securité de l’anticoagulation chez les patients avec cancer bronchique sans indication d’anticoagulant. Une revue systematique et meta analyse
Dr Philippe Debourdeau, ELSM 84, Avignon, fev 2013
Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factorbearing microparticles: a randomized-controlled phase II trial (the Microtec study).
Dr Philippe Debourdeau, ELSM 84, Avignon, fev 2013
Thromboembolisme arteriel chez les patients avec T&K traités par Cisplatine
Dr Philippe Debourdeau, ELSM 84, Avignon, Jan 2013
Risque veineux et Cisplatine
Dr Philippe Debourdeau, ELSM 84, Avignon, Jan 2013
La maladie thromboembolique veineuse à l’ASCO
Dr Philippe Debourdeau, hôpital Desgenettes, Lyon
DACUS: Un thrombus obstructif qui met du temps à se dissoudre.
Dr Philippe Debourdeau, hôpital Desgenettes, Lyon
Les anti agrégants plaquettaires s’accrochent.
Dr Philippe Debourdeau, hôpital Desgenettes, Lyon
Etude SAVE ONCO (Agnelli ASCO LBA9014)
Dr Philippe Debourdeau, hôpital Desgenettes, Lyon
Aspirin or enoxaparin thromboprophylaxis for newly-diagnosed multiple …
FRAGMINE (daltéparine)
Synthèse d’avis de la Commission de transparence
Janvier 2011
FRAGMINE (daltéparine)
Avis de la Commission de Transparence
30 juin 2010
Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide:A Phase III, Open-Label, Randomized Trial.
Palumbo A et al
J Clin Oncol. 2011 Jan 31. [Epub ahead of print]
Les D-Dimeres élevés sont aussi un marqueur de risque pour la TV chez les patients avec cancer
L Knowlson, S Bacchu, S Paneesha, A McManus, K Randall, P Rose.
J Clin Pathol 2010 63: 818-822
Par D. Farge
Commentaire (17/12/2010)
TROPICS 1: A Phase III, Randomized, Double-blind, Placebo-controlled Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters
Nashat Gabrail, MD, Eric Sandler, MD, Veena Charu, MD, Nick Anas, MD, Eduardo Lim, MD, Martha Blaney, PharmD, Mark Ashby, PhD, Barbara S. Gillespie, MD, and Susan M. Begelman, MD
J Vasc Interv Radiol 2010; 21:1852–1858
Commentaire (17/12/2010)
PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma.
Perry JR, Julian JA, Laperriere NJ, Geerts W, Agnelli G, Rogers LR, Malkin MG, Sawaya R, Baker R, Falanga A, Parpia S, Finch T, Levine MN.
J Thromb Haemost. 2010 Sep;8(9):1959-65.
Commentaire (17/12/2010)
Prediction of venous thromboembolism in cancer patients.
Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, Quehenberger P, Zielinski C, Pabinger I.
Blood. 2010 Dec 9;116(24):5377-82. Epub 2010 Sep 9.
Commentaire(17/12/2010)
Abstract